Arcus Biosciences, Inc.

This study tests a combination of two immunotherapy drugs (zimberelimab and domvanalimab) as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The goal is to see if the combination can slow or stop cancer growth …

This early-stage study tests a new drug called AB680 combined with three other medications (zimberelimab, nab-paclitaxel, and gemcitabine) in people with advanced pancreatic cancer that has not been treated before. The main goals are to check safety and find the right dose. About…

This large Phase 3 trial compares a new two-drug immunotherapy (domvanalimab and zimberelimab) plus chemotherapy against the standard immunotherapy (nivolumab) plus chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been tre…

This phase 3 trial tests whether adding the experimental drug quemliclustat to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 610 participants who have not yet been treated for advanced disease will receive either the drug combo or a place…

This phase 2 trial tests the safety and effectiveness of new drug combinations, with or without chemotherapy, in people with advanced stomach, GEJ, or esophageal cancer that cannot be removed by surgery or has spread. About 332 participants will receive treatments including FOLFO…

This early-phase study tests the safety of a new drug called AB598, given alone or with other treatments, in about 40 people with advanced solid tumors (e.g., lung, bladder, breast, or ovarian cancer). The main goal is to see if the drug is safe and tolerable. Participants must h…

This study tests a new drug called AB801, alone or with other treatments, in about 91 people with advanced cancers like lung, colon, breast, or ovarian cancer that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose. This i…